Milligrams of cosentyx for one psoriasis dose?

What is the standard Cosentyx dose for plaque psoriasis?

The approved dose for moderate to severe plaque psoriasis is 300 mg, given as two separate 150 mg subcutaneous injections at weeks 0, 1, 2, 3, and 4, then every 4 weeks.

Why do some patients receive only 150 mg?

Patients with lower body weight or those who respond well to initial treatment may stay on the 150 mg dose every 4 weeks after the loading phase. Your prescriber chooses the dose based on clinical response and tolerability.

How is the injection given in practice?

Each 150 mg dose comes in a prefilled syringe or pen. For the 300 mg dose, two devices are injected in different sites on the same day. Injections are given under the skin of the abdomen, thigh, or upper arm.

Can the dose be adjusted during treatment?

Dose reduction to 150 mg or temporary interruption is possible if side effects occur or infection risk rises. Increases above 300 mg are not recommended.

When does Cosentyx patent protection end?

U.S. patents covering Cosentyx expire in 2028, with some method-of-use patents extending into 2029. Biosimilar competition is not expected before late 2028 at the earliest. DrugPatentWatch.com tracks these dates.

What happens after patent expiry?

Biosimilar versions of secukinumab may reach the market once all regulatory and litigation hurdles clear. Pricing pressure and broader patient access typically follow biosimilar entry.